SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Alexion Pharmaceuticals, Inc. (ALXN)
An SI Board Since October 1997
Posts SubjectMarks Bans Symbol
824 29 0 ALXN
Emcee:  Larry Liebman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
274At this valuation it should make you feel like you are strapped to a rocket poinkeokalani'nui-4/28/2003
273short interest up sharply. nasdaq.com i've been trying to figure out the itom r. phillips-4/28/2003
272Therapeutic potential of targeting the complement cascade in critical care medicIcebrg-4/21/2003
271Toxicol Sci 2003 Mar 25; [epub ahead of print] A Correlation between a Proteomscaram(o)uche-3/28/2003
270Alexion Pharma 2Q Revenue $220,000 DOW JONES NEWSWIRES Alexion Pharmaceuticals Jim Oravetz-3/7/2003
269I guess WSJ article referral was for trial completion, not complete enrollment. Miljenko Zuanic-2/24/2003
268Alexion Completes Enrollment in Phase III Pivotal PRIMO-CABG Trial CHESHIRE, Conigel bates-2/24/2003
267<<I heard the same, but was corrected---they said that in in November at AMiljenko Zuanic-2/21/2003
266My hopeful expectation is 6 mo f/u and file BLA b4 YE03. AHA good time to announkeokalani'nui-2/21/2003
265>>they were over 2/3rd through enrollment of 3,000 patient primo-cabg phaskeokalani'nui-2/21/2003
264>>time to enrollment completion is moved bit forward<< I don't keokalani'nui-2/21/2003
263Last update I heard was they were over 2/3rd through enrollment of 3,000 patientrkrw-2/21/2003
262I did not confirmed, but appears that time to enrollment completion is moved bitMiljenko Zuanic-2/20/2003
261Honorable mention in the online WSJ. As this comes from a JAVA application, I dIan@SI-2/19/2003
260It is B6 derivative, pyridoxal-5'-phosphate or 3-hydroxy-2-methyl-5-[(phosphMiljenko Zuanic-1/14/2003
259From Co. PR, initiation of P2: <i>Medicure Inc. (CDNX:MPH) is pleased to keokalani'nui-1/14/2003
258Is this vitamin B? The company looks like a flake, but the investigators certkeokalani'nui-1/14/2003
257Intriguing. Press Release Source: Medicure Inc. Medicure Announces Positive RMiljenko Zuanic-1/14/2003
256lgnd/gsk TPO. Message 18409358keokalani'nui-1/6/2003
255CHESHIRE, Conn., Jan. 6 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. nigel bates-1/6/2003
254[465] Chemokine-Mediated Enhanced Megakaryocyte Motility Is Essential and Suffickeokalani'nui-12/16/2002
253Just in case folks hadn't seen this . . . >>CHESHIRE, Conn., Dec.tuck-12/5/2002
252>>No one better post this on biotech failures!! >> Perhaps, I may uIcebrg-11/18/2002
251It looks like lytic, just in the US, was nearly significant for mortality. Withkeokalani'nui-11/18/2002
250>>CHESHIRE, Conn., Nov. 18 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticatuck-11/18/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News